

Docket No.59 US

1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Leonard Bell
Application No: 10/047,608
Filing Date: January 14, 2002
For: Method of Prophylaxis Against Large
Myocardial Infarction

RECEIVED
OCT 20 2003
TECH CENTER 1600/2900

Mail Stop Non-Fee Amendment
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450


CERTIFICATE OF MAILING

Date of Deposit: October 14, 2003

I hereby certify that the following:

- ☒ This Certificate of Mailing
- ☒ Response to Restriction Requirement
- ☒ Return Postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to Mail Stop Non-Fee Amendment, Commissioner of Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.


Lori Rooney

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410



PATENT

Atty. Docket No: 59

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Leonard Bell

SERIAL NO. : 10/047,608

EXAMINER: F.P. Vandervegt

FILED : January 14, 2002

GROUP ART UNIT: 1676

FOR : Method of Prophylaxis Against Large Myocardial Infarction

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
OCT 20 2003
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Office Action mailed October 6, 2003 in connection with the above referenced application, please consider the following remarks.

REMARKS

Applicants elect to prosecute the claims of group 1, claims 1-13.

Despite the election, applicants traverse the restriction requirement. It is respectfully submitted that the Examiner should reconsider is the election of species requirement in view of the fact that the separate classification of the subject matter under the classification system of the United States Patent and Trademark Office is not conclusive proof of divisibility and further that the entire application must be examined as a whole when there would not be a serious burden on the Examiner. The fields of search are believed to be co-extensive for the two groups identified by the Examiner.

The Examiner is invited to contact the undersigned should he believe this would expedite prosecution of this application

Respectfully submitted

Dated: October 14, 2003



Mark Farber
Registration No.: 34,159
Attorney for Applicants

Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410
(203) 271-8319